
The publication of the GLOBE Final Rule provides important clarity on the administration's approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally....

Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer

Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...

The treatments are for eligible adults in England and Wales

True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.

Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it...

A new benchmark maps 100 UK prescription medicine companies across five maturity bands and finds a market at very different stages of digital development

It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year

Pharma teams often blame compliance when digital projects slow down. In reality, the bigger issue is usually weaker ownership, unclear review models and content structures that were never designed for...

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...